摘要
目的观察急性冠状动脉综合征（ACS）冠状动脉介入治疗（PCI）中应用国产替罗非班（欣维宁）后心脏不良事件及出血并发症的发生情况，并进一步评价欣维宁的有效性及安全性。方法200例ACS患者随机分为替罗非班组和对照组。全部患者均使用阿司匹林、氯吡格雷和肝素，且急诊或择期行PCI。替罗非班组在以上药物治疗的基础上，PCI术前或术中给予欣维宁。观察住院期间不良心脏事件、心肌灌注分级（TIMI 0～3级），术后出血事件及血小板情况。结果替罗非班组4周内主要不良心脏事件发生率较对照组显著降低（9％vs23％，P〈0.05）。围术期出血并发症较对照组稍高，但差异无统计学意义（P〉0．05）。两组术后出血并发症及血小板计数差异无统计学意义。结论ACS患者在PCI围术期应用欣维宁能进一步减少心肌缺血事件发生率，改善心肌灌注，安全性好。
Objective To observe the cardiac events and bleeding complication, evaluate the safety and efficacy of domestic Tirofiban （Xinweining） in the acute coronary syndrome （ACS）. Methods 200 patients which were performed percutaneous coronary intervention （PCI）. The ACS patient was randomly divided to two group, tirofiban group and control group. All patients used aspirin, clopidogrel and heparin, and was performed PCI. Tirofiban were used in PCI or after PCI. Observe the cardiac events, cardiac muscle perfusion （ TIMI 0 - 3 grade）, blooding events and blood platelet. Results The mainly cardiac events occurrence rate （include obstinate angina pectoris, AMI, die） in 4 weeks was distinctly decreased in tirofiban group （9% to 23%, P 〈 0.05 ）. Bleeding complication in tirofiban group was slightly higher than contrasting a group,but the difference had no statistics significance（P 〉 0.05 ）. After PCI, bleeding complication and platelet count difference between two groups had no statistics significance. Conclusion Xinweining could safety decrease cardiac events occurrence rate and improve the cardiac muscle perfusion in ACS patients which were performed PCI.
出处
《医学综述》
2009年第14期2220-2221,共2页
Medical Recapitulate
关键词
急性冠脉综合征
冠状动脉介入治疗
欣维宁
Acute coronary syndrome
Percutaneous coronary intervention
Xinweining
